Preference for Exercise vs. More Sedentary Reinforcers: Validation of an Animal Model of Tetrabenazine-Induced Anergia.

accumbens aversion binge eating depression dopamine reward voluntary exercise

Journal

Frontiers in behavioral neuroscience
ISSN: 1662-5153
Titre abrégé: Front Behav Neurosci
Pays: Switzerland
ID NLM: 101477952

Informations de publication

Date de publication:
2019
Historique:
received: 15 09 2019
accepted: 19 12 2019
entrez: 22 2 2020
pubmed: 23 2 2020
medline: 23 2 2020
Statut: epublish

Résumé

Physical activities can have intrinsic motivational or reinforcing properties. The choice to engage in voluntary physical activity is undertaken in relation to the selection of other alternatives, such as sedentary behaviors, drugs, or food intake. The mesolimbic dopamine (DA) system plays a critical role in behavioral activation or exertion of effort, and DA antagonism or depletion induces anergia in effort-based decision-making tasks. However, little is known about the neural mechanisms underlying the decision-making processes that establish preferences for sedentary vs. activity-based reinforcers. In the present work with male CD1 mice, we evaluated the effect of tetrabenazine (TBZ), a DA-depleting agent, on a three-choice T-maze task developed to assess preference between reinforcers with different behavioral activation requirements and sensory properties [i.e., a running wheel (RW) vs. sweet pellets or a neutral nonsocial odor]. We also studied the effects of TBZ on the forced swim test (FST), which measures climbing and swimming in a stressful setting, and on anxiety tests [dark-light (DL) box and elevated plus maze (EPM)]. In the three-choice task, TBZ reduced time running in the wheel but increased time spent consuming sucrose, thus indicating reduced activation but relatively intact sucrose reinforcement. The effect of TBZ was not mimicked by motivational manipulations that change the value of the reinforcers, such as making the RW aversive or harder to move, food-restricting the animals, inducing a binge-like eating pattern, or introducing social odors. In the FST, TBZ decreased time climbing (most active behavior) and increased immobility but did not affect anxiety in the DL or EPM. These results indicate that the three-choice T-maze task could be useful for assessing DA modulation of preferences for exercise based on activation and effort requirements, differentiating those effects from changes in preference produced by altering physical requirements, food restriction state, and stress during testing.

Identifiants

pubmed: 32082126
doi: 10.3389/fnbeh.2019.00289
pmc: PMC7002319
doi:

Types de publication

Journal Article

Langues

eng

Pagination

289

Subventions

Organisme : NIMH NIH HHS
ID : R03 MH094966
Pays : United States

Informations de copyright

Copyright © 2020 Carratalá-Ros, López-Cruz, SanMiguel, Ibáñez-Marín, Martínez-Verdú, Salamone and Correa.

Références

Neurology. 2013 Jan 22;80(4):409-16
pubmed: 23339207
J Comp Neurol. 2005 Dec 5;493(1):72-85
pubmed: 16255002
Neuropsychopharmacology. 2015 Mar;40(4):1005-15
pubmed: 25328051
Front Pharmacol. 2019 Jun 28;10:682
pubmed: 31316379
Eur J Pharmacol. 1984 Jul 20;102(3-4):425-30
pubmed: 6489435
Appetite. 2018 Jul 1;126:137-146
pubmed: 29627345
Physiol Behav. 2018 Jul 1;191:82-90
pubmed: 29653112
Trends Neurosci. 2015 Aug;38(8):465-7
pubmed: 26183088
Int J Neuropsychopharmacol. 2014 Dec;17(12):2045-56
pubmed: 24964269
J Appl Physiol (1985). 1992 May;72(5):1631-48
pubmed: 1601767
Med Sci Sports Exerc. 2016 Nov;48(11):2228-2238
pubmed: 27015386
Neuron. 2012 Nov 8;76(3):470-85
pubmed: 23141060
Neurotoxicology. 2015 Sep;50:71-80
pubmed: 26254738
Front Psychiatry. 2018 Sep 06;9:411
pubmed: 30237771
Psychopharmacology (Berl). 1987;92(2):180-5
pubmed: 3110839
J Affect Disord. 2000 Jan-Mar;57(1-3):83-93
pubmed: 10708819
J Comp Physiol Psychol. 1978 Oct;92(5):917-27
pubmed: 282297
Eur J Pharmacol. 1988 Dec 13;158(3):207-12
pubmed: 3253099
Pharmacol Biochem Behav. 1983 Jan;18(1):37-40
pubmed: 6828535
Behav Pharmacol. 1997 Nov;8(6-7):523-32
pubmed: 9832966
Mol Neurodegener. 2010 Apr 26;5:18
pubmed: 20420689
Neuropsychopharmacology. 2016 Feb;41(3):686-94
pubmed: 26105139
J Exp Anal Behav. 1969 Nov;12(6):861-74
pubmed: 16811415
Horm Behav. 2004 Sep;46(3):330-40
pubmed: 15325233
J Clin Psychiatry. 2002 Jan;63(1):7-8
pubmed: 11838630
Behav Brain Res. 2004 May 5;151(1-2):83-91
pubmed: 15084424
Behav Pharmacol. 2005 Jul;16(4):219-25
pubmed: 15961961
Psychopharmacology (Berl). 2015 Apr;232(7):1313-23
pubmed: 25323625
Neuropharmacology. 2018 Aug;138:349-359
pubmed: 29408363
Clin Ther. 2012 Jul;34(7):1487-504
pubmed: 22749259
Appetite. 2000 Feb;34(1):87-94
pubmed: 10744895
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:150-5
pubmed: 23665107
J Neurosci. 2013 Dec 4;33(49):19120-30
pubmed: 24305809
Neurosci Biobehav Rev. 2000 Mar;24(2):173-98
pubmed: 10714382
Nat Protoc. 2007;2(2):322-8
pubmed: 17406592
Behav Processes. 2014 Mar;103:35-42
pubmed: 24295809
J Comp Psychol. 1990 Mar;104(1):53-65
pubmed: 2354629
BMC Neurosci. 2014 Nov 19;15:124
pubmed: 25407014
Pharmacol Biochem Behav. 2015 Aug;135:217-26
pubmed: 26022661
Behav Brain Res. 1998 Mar;91(1-2):91-7
pubmed: 9578443
Psychopharmacology (Berl). 2016 Feb;233(3):393-404
pubmed: 26554387
Psychopharmacology (Berl). 2009 May;204(1):103-12
pubmed: 19132351
Pharmacol Biochem Behav. 2018 Mar;166:13-20
pubmed: 29309800
Brain. 2016 May;139(Pt 5):1325-47
pubmed: 27189581
Cogn Affect Behav Neurosci. 2012 Mar;12(1):74-84
pubmed: 22012275
Psychopharmacology (Berl). 1994 Dec;116(4):529-37
pubmed: 7701059
Physiol Behav. 2014 Jun 22;133:30-8
pubmed: 24832050
Dev Cogn Neurosci. 2011 Oct;1(4):444-58
pubmed: 22436566
J Nutr. 2003 Mar;133(3):831S-834S
pubmed: 12612162
J Comp Physiol Psychol. 1968 Aug;66(1):234-8
pubmed: 5672636
Am J Geriatr Pharmacother. 2010 Aug;8(4):331-73
pubmed: 20869622
Behav Brain Res. 2014 Aug 15;270:213-22
pubmed: 24859174
Behav Brain Res. 2002 Dec 2;137(1-2):3-25
pubmed: 12445713
Front Pharmacol. 2013 Nov 08;4:137
pubmed: 24265618
Behav Neurosci. 2015 Aug;129(4):457-72
pubmed: 26052795
Neuropharmacology. 2012 Apr;62(5-6):2068-77
pubmed: 22261384
Physiol Behav. 2018 Mar 1;185:95-102
pubmed: 29289614
Nat Protoc. 2012 May 03;7(6):1009-14
pubmed: 22555240
PLoS One. 2014 Jun 17;9(6):e99320
pubmed: 24937131
Front Behav Neurosci. 2018 Mar 23;12:52
pubmed: 29628879
Int J Neuropsychopharmacol. 2005 Mar;8(1):93-105
pubmed: 15482632
Neuropsychopharmacology. 2012 Sep;37(10):2194-209
pubmed: 22569506
PLoS One. 2012;7(10):e47934
pubmed: 23110135
Psychopharmacology (Berl). 2007 Apr;191(3):433-7
pubmed: 16977476
Psychopharmacology (Berl). 2020 Jan;237(1):33-43
pubmed: 31392358
Arch Int Pharmacodyn Ther. 1977 Oct;229(2):327-36
pubmed: 596982
Pharmacol Biochem Behav. 2019 Nov;186:172789
pubmed: 31499144
Psychopharmacology (Berl). 2016 Mar;233(6):949-60
pubmed: 26694811
Sports Med. 2015 Jul;45(7):997-1015
pubmed: 25771784
Behav Brain Res. 2015 Feb 15;279:100-5
pubmed: 25449845
Psychopharmacology (Berl). 1991;104(4):515-21
pubmed: 1780422
BMC Neurol. 2009 Dec 18;9:62
pubmed: 20021666
Behav Brain Res. 2017 Mar 15;321:8-17
pubmed: 28007538
Depress Anxiety. 2014 Mar;31(3):250-7
pubmed: 24115209
Psychopharmacology (Berl). 2015 Jul;232(13):2377-91
pubmed: 25647696
J Abnorm Psychol. 2012 Aug;121(3):553-8
pubmed: 22775583
Neuron. 2013 Jun 5;78(5):910-22
pubmed: 23764290

Auteurs

Carla Carratalá-Ros (C)

Àrea de Psicobiologia, Campus de Riu Sec, Universitat Jaume I, Castelló de la Plana, Spain.

Laura López-Cruz (L)

Àrea de Psicobiologia, Campus de Riu Sec, Universitat Jaume I, Castelló de la Plana, Spain.

Noemí SanMiguel (N)

Àrea de Psicobiologia, Campus de Riu Sec, Universitat Jaume I, Castelló de la Plana, Spain.

Patricia Ibáñez-Marín (P)

Àrea de Psicobiologia, Campus de Riu Sec, Universitat Jaume I, Castelló de la Plana, Spain.

Andrea Martínez-Verdú (A)

Àrea de Psicobiologia, Campus de Riu Sec, Universitat Jaume I, Castelló de la Plana, Spain.

John D Salamone (JD)

Behavioral Neuroscience Division, University of Connecticut, Storrs, CT, United States.

Mercè Correa (M)

Àrea de Psicobiologia, Campus de Riu Sec, Universitat Jaume I, Castelló de la Plana, Spain.

Classifications MeSH